Abstract
carcinoma (EAC) cells. Three weeks later, the mice were killed, and the tumors were surgically removed and weighed. Serum samples were collected from the mice, and antibody titers were determined by ELISA using an alkaline phosphate-conjugated detection antibody for total IgG. Antibody-dependent cell-mediated cytotoxicity was detected by the lactate dehydrogenase method using natural killer cells as effectors and antibody-labeled EAC cells as targets. Cytotoxic T lymphocyte activities were also detected by the lactate dehydrogenase method using lymphocytes as effectors and EAC cells as targets.
RESULTS:
Vaccines were successfully synthesized and validated by analytical high performance liquid chromatography and electrospray mass spectrometry, including T7, T7-MG1, and T7-MG3. Rapid inductions of tumor necrosis factor-α and interleukin-12 in bone marrow dendritic cells and interferon γ and interleukin-12 in lymphocytes occurred in vitro after T7, T7-MG1, and T7-MG3 treatment. Immunization with T7-MG3 reduced the EAC tumor burden in BALB/c mice to 62.64 ± 5.55% compared with PBS control (P < 0.01). Six or nine weeks after the first immunization, the monoclonal gastric cancer 7 antigen antibody increased significantly in the T7-MG3 group compared with the PBS control (P < 0.01). As for antibody-dependent cell-mediated cytotoxicity, antisera obtained by immunization with T7-MG3 were able to markedly enhance cell lysis compared to PBS control (31.58 ± 2.94% vs 18 .02 ± 2.26%; P < 0.01). As for cytotoxic T lymphocytes, T7-MG3 exhibited obviously greater cytotoxicity compared with PBS
INTRODUCTION
Gastric cancer is one of the most common malig nancies and the second leading cause of cancer related death worldwide. Surgery, chemotherapy, and radiotherapy are frequently used in the treatment of gastric cancer. Immunotherapy, especially tumor vaccine, has now drawn more and more attention for its advantages, such as low toxicity and longterm effect. However, due to the lack of tumorspecific antigens, few effective gastric cancer vaccines have been investigated.
Monoclonal gastric cancer 7 antigen (MG7Ag), discovered by Dr. Fan DaiMing (the Fourth Military Medical University, Xi'an, China), is a tumorassociated antigen with high specificity and selectivity. MG7 Ag expression in gastric mucosa is closely associated with high risk of gastric atypical hyperplasia and malignant change, which suggests that MG7Ag plays an important role in gastric cancer progression [1, 2] . Many studies have been carried out concerning tumor prevention and treatment based on MG7 Ag, including DNA vaccines and recombinant protein vaccines [3, 4] . However, weak immunogenicity of tumor associated antigens is a drawback of tumor vaccines, which requires the addition of adjuvants for optimal performance.
Tolllike receptors (TLRs) are fundamental elements of immune system, which facilitate our understanding of the innate and adaptive immunity. The application of TLR ligands as adjuvants in vaccine development is currently under intensive investigation, as they are not only capable of protecting against infectious diseases [5, 6] , but also serving as a promising method for cancer treatment [7, 8] . Evidence has revealed that vaccinemediated tumor inhibition was caused by specific immunity against MUC1 and nonspecific adjuvant effects of the TLR2 agonist [9] . Among all kinds of TLR ligands, the TLR7 agonist is the only choice of small molecule synthetic compound, which is more convenient to obtain than other biomacromolecules, such as TLR4 and TLR9 ligands. The TLR7 agonist has also been reported with immunostimulatory capacity, and applied in the research of vaccines against several types of tumors, such as leukemia and breast cancer [10, 11] . Imiquimod, the classic TLR7 agonist, lacks the chemical group to couple with proteins or peptides. Therefore, we adopted another wellstudied TLR7 agonist (T7; chemical structure is shown in Figure 1 ) where its free carboxyl group can link to the amino group of peptides [12] . Here, we constructed a novel gastric cancer vaccine by covalently coupling the small molecule T7 with MG7Ag monoepitope (MG1; sequence used widely in tumor vaccines), and examined its efficiency in eliciting humoral and cellular immune response, reversing tumor tolerance, and generating a protective effect. Furthermore, we designed an MG7Ag triepitope (MG3; epitope sequence repeated three times) as a superantigen, and conjugated it with T7 to constitute a more potent vaccine. Our research revealed that conjugation of T7 and MG3 was critical for inducing optimal immune responses, displayed by cytokine detection, antibody titer determination, antibody dependent cellmediated cytotoxicity (ADCC), cytotoxic T lymphocyte (CTL) activity, and a tumor challenge assay.
MATERIALS AND METHODS

Chemical synthesis
T7 was synthesized as described before [12] . The peptides were synthesized by solid phase using an Fmoc strategy [13] . 2Chlorotrityl chloride resin (GL BIO Company, Shanghai, China) was the solid support loaded at 1.0 mmol/g. The following Nprotected Fmoc amino acids were applied as the functionalized amino acids: FmocLys(Boc)OH, FmocThr(tBu)OH, Fmoc His(Trt)OH, FmocValOH, FmocProOH (GL BIO Company, Shanghai, China) and T7. For the synthesis, 2(1 Hbenzotriazol1yl)1,1,3,3tetramethyluronium hexafluorophosphate was used as the coupling reagent, while each amino acid was used at eight equal molar quantities. Fmoc deprotection was carried out in a mixture of piperidine and dimethylformamide at a ratio of 2:8 (v/v). Disaggregation of the peptide from the resin was performed for 3.5 h in a solution containing trifluoroacetic acid, phenol, water, and triisprpylsilane at a ratio of 88:5:5:2 (v/v). Following addition of cold diethyl ether for precipitation, peptides were dissolved with 0.1% trifluoroacetic acid in water/ acetonitrile and lyophilized. Finally, a purity of at least 95% (UV detection at 214 nm and 254 nm) in all peptides was validated by analytical high performance liquid chromatography using a C18 column (5 µm, 300 Å, 10 mm × 200 mm). Electrospray mass spectrometry was also performed to further identify the peptides.
Cytokine assays
Cytokines were measured in both mouse bone marrow dendritic cells (BMDCs) and mouse spleen lymphocytes. BMDCs were generated as described previously [14] . Briefly, bone marrow cells from femurs and tibiae of BALB/c mice were cultured at 37 ℃ for 6 d in Xvivo 15 medium (Lonza Group, Basel, Switzerland) containing granulocytemacrophage colonystimulating factor (GMCSF) (10 ng/mL) and interleukin (IL)4 (10 ng/mL). Spleen lymphocytes were isolated from BALB/c mice using Mouse Lymphocyte Separation Medium (Dakewe, Beijing, China), according to the supplier's manual. BMDCs and lymphocytes were seeded in 96well plates at a density of 5 capture antibody overnight at 4 ℃, and then filled successively with block solution, culture supernatant, and detection antibody for 1 h at room temperature. Finally, substrate and stop solution were added to each well, and the optical density was measured at 450 nm with a spectrophotometer (BioTek, Winooski, VT, United States).
Immunization of mice
This study was approved by the Laboratory Animal Ethics Committee of Shenzhen University. The animal protocol was designed to minimize pain or discomfort to the animals. Female 4wkold BALB/c mice weighing 1520 g were purchased from the Medical Laboratory Animal Center (Guangzhou, Guangdong, China). All mice were housed in constant laboratory conditions of a 12 h light/dark cycle and specific pathogen free conditions, and fed with water and food ad libitum. After being acclimated for 1 wk, BALB/c mice were used to evaluate the immunogenicity of the vaccines, by immunizations with T7, MG1, T7+MG1 (unconjugated), T7MG1 (conjugated), MG3, T7+MG3 (unconjugated), T7MG3 (conjugated), and PBS as control. For these experiments, 25 µg of T7MG3 or equal molar quantities of other vaccines were administered i.p. to each mouse every 2 wk for a total of three times.
Tumor challenge assays
After 6 wk immunizations, each BALB/c mouse was subcutaneously challenged with 1 × 10 7 Ehrlich ascites carcinoma (EAC) cells, and the expression of MG7Ag was assessed by Western blot using MG7Ag antibody (a gift from Dr. Fan DaiMing and Dr. Nie YongZhan). Three weeks after challenge, the mice were killed, and the tumors were surgically removed and weighed.
Determination of antibody titers
After each immunization, blood samples were collected from the mice and centrifuged at 3000 × g for 15 min to obtain serum samples. Antibody titers in serum were determined by ELISA using an alkaline phosphateconjugated detection antibody for total IgG (Millipore Corp., Billerica, MA, United States). Briefly, an ELISA plate was coated with BSAMG1 (peptide sequence is BSAKPHVHTK) overnight at 4 ℃, then incubated successively with block solution for 2 h, serum samples (1:50 diluted), and detection antibody for 1 h at room temperature. Finally, pNPP substrate (Millipore Corp.) and stop solution were added to each well, and the optical density was measured at 405 nm with a spectrophotometer (BioTek). 
Determination of ADCC
Determination of CTL
At the time of sacrifice, lymphocytes, separated from the spleen of each mouse by Mouse Lymphocyte Separation Medium (Dakewe, Beijing, China), were used as effectors. EAC tumor cells were used as target cells and incubated with lymphocytes for 4 h at an effectortotarget cell ratio of 100:1. Cytotoxicity was also measured by the LDH method as described above.
Statistical analysis
Data are expressed as mean ± SE for the indicated number of independently performed experiments. Student's t test was used for the determination of statistical significance. The difference was considered to be statistically significant at P < 0.05. The statistical methods of this study were reviewed by Dr. Gao Kai Ping from the School of Medicine, Shenzhen University.
RESULTS
Chemical synthesis of vaccines
T7 was synthesized as described above and used in the preparation of other vaccines ( Figure 1 ). The following four peptides were synthesized by solid phase method: MG1 (peptide sequence is KPHVHTK), MG3 (peptide sequence is KPHVHTKPHVHTKPHVHTK), T7MG1, and T7MG3. T7 and MG7Ag were also used in combination without chemical conjugation by mixing equal molar quantities of T7 and MG1 (T7+MG1) or MG3 (T7+MG3). All of abovementioned compounds were confirmed by mass spectrometry and high performance liquid chromatography.
In vitro cytokine release by vaccines
To examine the activity on initiating the production of necessary cytokines, mouse BMDCs and spleen lymphocytes were exposed to vaccines at indicated concentrations. As shown in Figure 2A and B, the levels of two cytokines (TNFα and IL12) remained unchanged when the BMDCs were incubated with MG1 or MG3 alone. However, T7 displayed dosedependent increases of TNFα release in the range of 0.1 μmol/L to 10 μmol/L, and IL12 release in the range of 1 μmol/L to 10 μmol/L. Significantly higher levels of cytokines were detected when the MG7Ag epitope was conjugated to T7 (T7MG1 or T7MG3) compared to T7 alone (P < 0.05). Moreover, 10 μmol/L T7MG3 was more potent in raising cytokine release levels of TNFα and IL12 than T7MG1. Similar results were demonstrated for cytokines released in lymphocytes ( Figure 2C, D) . Furthermore, 0.1 μmol/L T7MG3, rather than 0.1 µmol/L T7MG1, increased the levels of IFNγ and IL12, indicating that T7MG3 had a stronger stimulating effect on mouse lymphocytes than T7MG1.
Protection of vaccines against tumor challenge
EAC cells, which have been verified for the presence of MG7Ag [3] , were used to challenge the BALB/c mice to investigate the protective ability of tumor vaccines. We also confirmed the expression of MG7-Ag in EAC cells by Western blot (data not shown). As shown in Figure  3 , immunization with T7, MG1, or MG3 alone did not exhibit much improvement of antitumor properties as compared with PBS control. Although T7+MG1 and T7 MG1 led to somewhat smaller tumors, their differences Wang XD et al . TLR7 agonist exerts antitumor effects
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were not significant compared with PBS control. Obvious reduction of tumor weight was observed when T7 was used together with the MG3, whether as a commixture (T7+MG3) or chemical conjugation (T7 MG3); the difference between T7+MG3 and T7MG3 was not significant. Meanwhile, mouse breast cancer 4T1 cells (absence of MG7Ag expression ascertained by Western blot) were included as a negative control. Neither T7+MG3 nor T7MG3 could reduce the 4T1 tumor burden (data not shown), indicating the MG7 Ag specificity of the observed effects in EAC cells.
Serum antibody induced by vaccines
Serum antibody titers against MG7Ag were determined by ELISA assay. Six or nine weeks after first immu nization, MG7Ag antibody increased significantly in T7+MG3 and T7MG3 groups compared to PBS control, while the difference of immune effect was negligible between chemical conjugation (T7MG3) and simple commixture (T7+MG3). On the other hand, T7, MG1, or MG3 alone exerted little impact on MG7 Ag antibody (Figure 4 ). Vaccines constructed with MG1 (T7+MG1 and T7MG1) also could not elicit antibody response, independent of the times of immunization (data not shown).
ADCC induced by vaccines
ADCC was determined by addition of serum samples and NK cells (cytotoxic effector cells) to EAC tumor cells (target cells), and measurement of released LDH activity ( Figure 5 ). Antisera collected from the mice immunized with T7 and MG1, whether used alone or in combination (T7+MG1 or T7MG1), did not induce significant cancer cell lysis compared with PBS control. Antibodies derived from MG3 displayed stronger cytotoxicity to a certain degree, yet still not significantly different from the PBS control. However, antisera obtained by immunization with T7+MG3 and T7MG3 were able to markedly increase cell lysis compared to PBS or MG3 alone. No remarkable ADCC effect of vaccines was found when mouse breast cancer 4T1 cells were used as target cells for negative control (data not shown).
CTL induced by vaccines
To assess the ability of vaccines to activate cellular immunity, CTL activity was determined by LDH assay, which is identically sensitive to the 51 Cr release assay when measuring cytotoxicity. As shown in Figure 6 , immunization with T7, MG1, or MG3 alone did not induce more CTL in BALB/c mice than in PBS control. As expected, CTL activated by T7+MG3 and T7MG3 exhibited obviously greater cytotoxicity compared with control, being significantly higher with T7MG3 compared to T7+MG3 (P < 0.05). However, vaccines constructed with MG1, both T7+MG1 and T7MG1, did not display similar high lytic activity as with T7+MG3 and T7MG3. Similar with ADCC, no CTL effect of vaccines was detected with 4T1 cells as negative control (data not shown).
DISCUSSION
Gastric cancer is the second leading cause of cancer related death worldwide, and therapeutic effect was poor by traditional treatment (surgery, chemotherapy, and radiation) with a low fiveyear survival rate. Therefore, immunotherapy offers another direction in prevention and treatment of gastric cancer. Nowadays, adoptive cell therapy, gene therapy, monoclonal antibody therapy, and cancer vaccines are frequently used with some success [15] . Clinical studies of adoptive immunotherapies have shown that longer survival was achieved in gastric cancer patients treated with chemotherapy in combination with tumorassociated Figure 4 Vaccines induced serum antibody against monoclonal gastric cancer 7 antigen in BALB/c mice. Every two weeks after immunization (week 2, 4, 6) and after sacrifice (week 9), serum samples were collected and antibody titers were determined by ELISA. Data points represent mean ± SE (n = 5); a P < 0.05, b P < 0.01 vs control group. MG3: monoclonal gastric cancer 7 antigen tri-epitope; T7: Toll-like receptor-7 agonist. lymphocytes or cytokineinduced killer cells than with chemotherapy alone [16, 17] . As for cancer vaccines, nanoparticles with the melanomaassociated antigen 3 peptide show the ability to stimulate immune responses in vivo and kill mouse forestomach carcinoma cells [18] . Vaccination with human vascular endothelial growth factor receptors 1 and 2 combined with chemotherapy is well tolerated and highly effective in advanced or recurrent gastric cancer [19] . Occurrence of novel tumor antigen is one of the most important immunologic characteristics of tumor cells. So far, many tumorassociated antigens have been explored and applied in the research of tumor vaccines in order to elicit specific immune responses in the host, either by themselves or after loading onto antigen presenting cells. SipuleucelT, containing prostate acid phosphatase antigen, is the first cellbased immunotherapeutic vaccine approved by the Food and Drug Administration for patients with metastatic castrationresistant prostate cancer [20] . Clinical data have also shown that therapeutic cancer vaccine targeting the MUC1 antigen is effective in nonsmall cell lung cancer patients [21] . MG7-Ag, first discovered in the KATO III cell line, is one kind of gastric cancerassociated antigen and is expressed at a high level in the serum and tissue of gastric cancer patients [22] . Recently, it has been investigated as a biomarker with high sensitivity and specificity for gastric cancer diagnosis [23] , and many methods for MG7Ag detection are being developed, such as immunohistochemical stain and ELISA [24, 25] . It is worth noting that MG7Ag has also been applied in the development of tumor vaccines. Heterologous primeboost immunization with oral MG7Ag DNA vaccine induces significant immune response to gastric cancer [3] . A fusion protein containing MG7 Ag antibody and superantigen staphylococcal enterotoxin B has been constructed with the ability to kill SGC7901 human gastric cancer cells [4] . Despite the potency of the MG7Ag against cancer shown by previous studies, MG7Ag epitope peptides are much more widely used in current gastric cancer vaccines, circumventing the difficulty of isolating and purifying MG7Ag directly from tumor tissue. Moreover, a multi repeatepitope is a welldefined strategy of vaccine construction for enhancing the effect of immunization, which has also been adopted in MG7Ag epitope based research [26] . Therefore, in this study, MG7Ag monoepitope and triepitope peptides were used as antigens and expected to achieve specific antitumor effect. However, neither MG1 nor MG3 alone had much impact on immunity enhancement of BALB/c mice, displayed as a minimal change of antibody titers, ADCC, CTL (in vivo), and cytokine induction (in vitro) after antigen immunization. MG1 and MG3 alone also could not efficiently inhibit the growth of EAC tumor cells in vivo. These results confirm the fact that tumorrelated antigens, especially epitopes, are often poorly immunogenic and do not sufficiently activate immune cells for recognizing and invading the tumor cells.
Several studies have demonstrated that conju gations of TLR7 ligands and antigens trigger better immunogenicity compared to noncoupled antigens alone [27] . Oh et al [28] showed that a TLR7 agonistAg conjugate elicited CD8 + T cell responses based on the engagement of DC crosspresentation pathways. Similarly, we used a promising small molecule compound (T7) for the attachment to MG7Ag in the study of tumor immunotherapy. Chemical conjugation of this agonist and mouse serum albumin resulted in 10100fold potent cytokine production in vitro, and significant delay in mortality in BALB/c mice inoculated with influenza virus [29] . When the compound was conjugated to phospholipid and administered systemically in mice, prolonged increases occurred in the levels of proinflammatory cytokines. The phospholipidTLR7 agonist conjugate could be further used as adjuvant during vaccination, which resulted in the boost of both Th1 and Th2 antigenspecific immune responses [12] . The data presented here showed that T7 improved the innate immunity by rapid induction of inflammatory mediators TNFα and IL12 in BMDCs and IFNγ and IL12 in lymphocytes in vitro, while the conjugation (T7MG1 or T7MG3) yielded more potent effects. Cytokines produced following the activation of TLR7 can stimulate the expression of costimulatory proteins for optimum interactions between helper T, B, and antigen presenting cells [9] . Therefore, covalent attachment of T7 and MG7Ag is critical for the induction of adaptive immunity, including CTLs and antibodies. Indeed, vaccination with T7MG3 reduced the EAC tumor burden in vivo, via eliciting cytotoxicity of T lymphocytes and IgG antibodies that could specifically lyse cancer cells. The results of the present study also showed that the differences between T7MG3 and PBS control in CTL activities were more noticeable than in antibody titers and ADCC activities, implying that cellular immunity made a greater contribution than humoral immunity to the vaccination of T7MG3.
Over the past decade, numerous studies have been carried out concerning how to promote antigen presentation for improving immune responses, such as with heat shock proteins or bacterial toxins linked to antigens [30] . These strategies for DC uptake have the disadvantage that immune suppression might occur due to the antigenicity of the targeting device, which could be avoided by the low intrinsic immunity of small molecule T7. Meanwhile, no remarkable effect of T7+MG1 or T7MG1 was observed on either the promotion of immunity or the reduction of tumor, revealing the importance of multirepeatepitope used for vaccine development. As for MG3, chemical conjugation with T7 was more effective than simple commixture when for vaccination of BALB/c mice, especially on the induction of CTLs. Thus, based on the existing reports and the results present here, it is reasonable to suppose that covalent attachment is a better method for the investigation of vaccines than simple mixture, considering that distribution and metabolism of T7 and antigen could be more coincident systemically.
In conclusion, an effective tumor vaccine targeting MG7Ag has been constructed by chemical conjugation of T7 with MG3. Its capacity was ascertained to generate CTLs and ADCCmediating antibodies recognizing MG7 Ag and provide a therapeutic benefit in EAC tumor bearing mice. T7 could elicit the nonspecific antitumor responses and strengthen the specific humoral and cellular immune responses, which is imperative in tumor vaccines due to the fact that tumor antigens rarely possess immunogenicity. This concept of vaccine construction can be further applied in other kinds of tumors, either as single immunotherapy or combined with other therapies.
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COMMENTS
Background
Gastric cancer is one of the most common malignant tumors, in which tumor vaccines play increasingly important roles for their advantages, such as low toxicity and long-term effect. Weak immunogenicity of tumor-associated antigens and lack of immune recognition are main reasons that tumor cell escape surveillance and eradication by the immune system, thus requiring the addition of adjuvant for optimal performance of tumor-associated antigens.
Research frontiers
Recently, monoclonal gastric cancer 7 antigen (MG7-Ag) was investigated as a biomarker with high sensitivity and specificity for gastric cancer diagnosis, and many detecting methods are being developed, such as immunohistochemical stain and ELISA. It is worth noting that MG7-Ag has also been applied in the development of tumor vaccines, such as DNA and recombinant protein vaccines. On the other hand, the applications of toll-like receptor (TLR) ligand as an adjuvant in vaccine development are under intensive investigation, against not only infectious diseases, but also malignant tumors.
Innovations and breakthroughs
In this study, the authors constructed tumor vaccines by covalent attachment of MG7-Ag and a TLR7 agonist (T7). Conjugation of T7 with an MG7-Ag tri-epitope (T7-MG3) significantly increased the release of tumor necrosis factor-α and interluekin-12 in bone marrow dendritic cells and interferon-γ and interleukin-12 in mouse lymphocytes in vitro. Immunization with T7-MG3 was efficacious in reversing tolerance and generating therapeutic response in Ehrlich ascites carcinoma-bearing mice, through enhancing specific humoral and cellular immunity, which were displayed as higher antibody titers, antibodydependent cell-mediated cytotoxicity, cytotoxic T lymphocyte activity. Although a simple commixture of T7 and MG3 was able to inhibit tumor growth in tumorbearing mice because of the immune enhancement, the effects of T7-MG3 were greater, especially on the induction of cytotoxic T lymphocytes. However, vaccines with an MG7-Ag mono-epitope showed no significant effect on either the promotion of immunity or the reduction of tumor size.
Applications
This study demonstrated a successful way for the design of gastric cancer vaccines by combined use of T7 and MG7-Ag, and the importance of multirepeat-epitopes and chemical conjugation. This concept of vaccine construction can be further applied in other kinds of tumors, either as single immunotherapy or combined with other therapies.
Terminology
MG7-Ag is a tumor-associated antigen with high specificity and selectivity, whose expression in gastric mucosa is closely associated with high risk of gastric atypical hyperplasia and malignant change. Among all kinds of TLR ligands, the TLR7 agonist is the only choice of small molecule synthetic compounds, which is more convenient to obtain than other ligands.
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